Cytochrome P4502C9: an enzyme of major importance in human drug metabolism.

Accumulating evidence indicates that CYP2C9 ranks amongst the most important drug metabolizing enzymes in humans. Substrates for CYP2C9 include fluoxetine, losartan, phenytoin, tolbutamide, torsemide, S-warfarin, and numerous NSAIDs. CYP2C9 activity in vivo is inducible by rifampicin. Evidence suggests that CYP2C9 substrates may also be induced variably by carbamazepine, ethanol and phenobarbitone. Apart from the mutual competitive inhibition which may occur between alternate substrates, numerous other drugs have been shown to inhibit CYP2C9 activity in vivo and/or in vitro. Clinically significant inhibition may occur with coadministration of amiodarone, fluconazole, phenylbutazone, sulphinpyrazone, sulphaphenazole and certain other sulphonamides. Polymorphisms in the coding region of the CYP2C9 gene produce variants at amino acid residues 144 (Arg144Cys) and 359 (Ile359Leu) of the CYP2C9 protein. Individuals homozygous for Leu359 have markedly diminished metabolic capacities for most CYP2C9 substrates, although the frequency of this allele is relatively low. Consistent with the modulation of enzyme activity by genetic and other factors, wide interindividual variability occurs in the elimination and/or dosage requirements of prototypic CYP2C9 substrates. Individualisation of dose is essential for those CYP2C9 substrates with a narrow therapeutic index.

[1]  M. Eadie,et al.  Extent of urinary excretion of p-hydroxyphenytoin in healthy subjects given phenytoin. , 1985, Therapeutic drug monitoring.

[2]  D. Mansuy,et al.  The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. , 1995, Biochemistry.

[3]  F. Iber.  Drug metabolism in heavy consumers of ethyl alcohol , 1977, Clinical pharmacology and therapeutics.

[4]  J. Goldstein,et al.  Biochemistry and molecular biology of the human CYP2C subfamily. , 1994, Pharmacogenetics.

[5]  C. Crespi,et al.  The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. , 1997, Pharmacogenetics.

[6]  J. Miners,et al.  Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. , 1993, The Biochemical journal.

[7]  D. Abernethy,et al.  Selective inhibition of warfarin metabolism by diltiazem in humans. , 1991, The Journal of pharmacology and experimental therapeutics.

[8]  R. Gugler,et al.  Interaction between metronidazole and drugs eliminated by oxidative metabolism , 1985, Clinical pharmacology and therapeutics.

[9]  J. Goldstein,et al.  Correlation of human cytochrome P4502C substrate specificities with primary structure: warfarin as a probe. , 1993, Molecular pharmacology.

[10]  M. Milad,et al.  Contrasting effects of fluconazole and ketoconazole on phenytoin and testosterone disposition in man. , 1992, British journal of clinical pharmacology.

[11]  J. Miners,et al.  Normal metabolism of debrisoquine and theophylline in a slow tolbutamide metaboliser. , 1985, Australian and New Zealand journal of medicine.

[12]  S. Thompson,et al.  Factors affecting the maintenance dose of warfarin. , 1992, Journal of clinical pathology.

[13]  D J Greenblatt,et al.  Pharmacokinetics and pharmacodynamics. , 1990, Hospital practice.

[14]  H. Yamazaki,et al.  Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[15]  J. Miners,et al.  Relationship between phenytoin and tolbutamide hydroxylations in human liver microsomes. , 1991, British journal of clinical pharmacology.

[16]  S. Wrighton,et al.  Role of cytochrome P450 2C9 and an allelic variant in the 4'-hydroxylation of (R)- and (S)-flurbiprofen. , 1995, Biochemical pharmacology.

[17]  S. Vožeh,et al.  Pharmacokinetic Drug Data , 1988, Clinical pharmacokinetics.

[18]  D. Mansuy,et al.  Human-liver cytochromes P-450 expressed in yeast as tools for reactive-metabolite formation studies. Oxidative activation of tienilic acid by cytochromes P-450 2C9 and 2C10. , 1993, European journal of biochemistry.

[19]  L. Wienkers,et al.  Warfarin-fluconazole. II. A metabolically based drug interaction: in vivo studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[20]  S. London,et al.  Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. , 1997, Pharmacogenetics.

[21]  S. Pond,et al.  Mechanisms of inhibition of tolbutamide metabolism: Phenylbutazone, oxyphenbutazone, sulfaphenazole , 1977, Clinical pharmacology and therapeutics.

[22]  D. Back,et al.  In vitro inhibition studies of tolbutamide hydroxylase activity of human liver microsomes by azoles, sulphonamides and quinolines. , 1988, British journal of clinical pharmacology.

[23]  Jeffrey P. Jones,et al.  Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[24]  W. Trager,et al.  Genetic association between sensitivity to warfarin and expression of CYP2C9*3. , 1997, Pharmacogenetics.

[25]  P. Beaune,et al.  Intralobular distribution and quantitation of cytochrome P‐450 enzymes in human liver as a function of age , 1991, Hepatology.

[26]  P. Beaune,et al.  Tienilic acid-induced autoimmune hepatitis: anti-liver and-kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9. , 1996, Molecular pharmacology.

[27]  M. Gibaldi,et al.  The warfarin‐sulfinpyrazone interaction: stereochemical considerations , 1986, Clinical pharmacology and therapeutics.

[28]  R. Weaver,et al.  Cytochrome P450 2C9 is responsible for hydroxylation of the naphthoquinone antimalarial drug 58C80 in human liver. , 1993, Biochemical pharmacology.

[29]  A. Breckenridge,et al.  CIMETIDINE: INTERACTION WITH ORAL ANTICOAGULANTS IN MAN , 1979, The Lancet.

[30]  K. Korzekwa,et al.  Predicting the cytochrome P450 mediated metabolism of xenobiotics. , 1993, Pharmacogenetics.

[31]  S D Hall,et al.  Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. , 1997, Biochemical pharmacology.

[32]  L. Wienkers,et al.  Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[33]  D W Nebert,et al.  P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. , 1996, Pharmacogenetics.

[34]  A. Breckenridge,et al.  Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. , 1974, The Journal of clinical investigation.

[35]  F. Iber,et al.  Increased Rate of Clearance of Drugs from the Circulation of Alcoholics* , 1969, The American journal of the medical sciences.

[36]  D. Greenblatt,et al.  Human cytochromes mediating N-demethylation of fluoxetine in vitro , 1997, Psychopharmacology.

[37]  W. Trager,et al.  Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. , 1996, Archives of biochemistry and biophysics.

[38]  G. Shenfield,et al.  A screening test for slow metabolisers of tolbutamide. , 1991, British journal of clinical pharmacology.

[39]  G. Smith,et al.  Ketoconazole and sulphaphenazole as the respective selective inhibitors of P4503A and 2C9. , 1995, Xenobiotica; the fate of foreign compounds in biological systems.

[40]  T. Ishizaki,et al.  Genetic analysis of CYP2C9 polymorphism in a Japanese population. , 1997, Pharmacogenetics.

[41]  M. Gibaldi,et al.  Mechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects , 1992, Clinical pharmacology and therapeutics.

[42]  M. Gibaldi,et al.  The mechanism of the warfarin‐rifampin drug interaction in humans , 1987, Clinical pharmacology and therapeutics.

[43]  M. Kristensen,et al.  SULPHAPHENAZOLE-INDUCED HYPOGLYCAEMIC ATTACKS IN TOLBUTAMIDE-TREATED DIABETICS. , 1963, Lancet.

[44]  P. Höglund,et al.  Stereoselective Interaction of Omeprazole with Warfarin in Healthy Men , 1989, Therapeutic drug monitoring.

[45]  D. Mansuy,et al.  Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes. Catalysis by a cytochrome P450 IIC different from that responsible for mephenytoin hydroxylation. , 1991, Biochemical pharmacology.

[46]  T. Leemann,et al.  Cytochrome P450TB (CYP2C): a major monooxygenase catalyzing diclofenac 4'-hydroxylation in human liver. , 1993, Life sciences.

[47]  N. Hastie,et al.  Human cytochrome P-450 PB-1: a multigene family involved in mephenytoin and steroid oxidations that maps to chromosome 10. , 1988, American journal of human genetics.

[48]  J. Miners,et al.  Chapter 31. In Vitro Approaches for the Prediction of Human Drug Metabolism , 1994 .

[49]  E. Sellers,et al.  Effect of short‐ and long‐term alcohol use on phenytoin kinetics in chronic alcoholics , 1981, Clinical pharmacology and therapeutics.

[50]  P. Beaune,et al.  Contribution of human cytochrome P450 to benzo[a]pyrene and benzo[a]pyrene-7,8-dihydrodiol metabolism, as predicted from heterologous expression in yeast. , 1996, Pharmacogenetics.

[51]  T. Shimada,et al.  Human liver microsomal cytochrome P-450 mephenytoin 4-hydroxylase, a prototype of genetic polymorphism in oxidative drug metabolism. Purification and characterization of two similar forms involved in the reaction. , 1986, The Journal of biological chemistry.

[52]  P. Chakravarty,et al.  Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[53]  A. D. Rodrigues,et al.  Identification of cytochromes P450 involved in the human liver microsomal metabolism of the thromboxane A2 inhibitor seratrodast (ABT-001). , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[54]  K. Wilner,et al.  Drug interactions with fluconazole. , 1990, Reviews of infectious diseases.

[55]  W. Trager,et al.  Interaction of amiodarone with racemic warfarin and its separated enantiomorphs in humans , 1987, Clinical pharmacology and therapeutics.

[56]  G. Tucker,et al.  Cytochromes P450 mediating the N-demethylation of amitriptyline. , 2003, British journal of clinical pharmacology.

[57]  T. Leemann,et al.  In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)‐fluvastatin , 1995, Clinical pharmacology and therapeutics.

[58]  U. Meyer,et al.  Polymerase chain reaction-directed identification, cloning, and quantification of human CYP2C18 mRNA. , 1991, Molecular pharmacology.

[59]  F. Gonzalez,et al.  Metabolic activation of the potent carcinogen dibenzo[a,h]anthracene by cDNA-expressed human cytochromes P450. , 1996, Archives of biochemistry and biophysics.

[60]  H. Yamazaki,et al.  Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations. , 1997, Pharmacogenetics.

[61]  J. Miners,et al.  Co-regulation of phenytoin and tolbutamide metabolism in humans. , 1992, British journal of clinical pharmacology.

[62]  P. Srivastava,et al.  Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 (S)-mephenytoin 4'-hydroxylase. , 1988, Biochemistry.

[63]  D. Back,et al.  Genetic factors influencing the metabolism of tolbutamide. , 1989, Pharmacology & therapeutics.

[64]  L. Wienkers,et al.  Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. , 1994, Pharmacogenetics.

[65]  T. Inaba,et al.  Identification of cytochromes P450 involved in human liver microsomal metabolism of ecabapide, a prokinetic agent. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[66]  J. Miners,et al.  Specificity of the inhibitory effect of dextropropoxyphene on oxidative drug metabolism in man: effects on theophylline and tolbutamide disposition. , 1987, British journal of clinical pharmacology.

[67]  J. Miners,et al.  Tolbutamide hydroxylation by human liver microsomes. Kinetic characterisation and relationship to other cytochrome P-450 dependent xenobiotic oxidations. , 1988, Biochemical pharmacology.

[68]  M. Kristensen,et al.  Influence of rifampicin and isoniazid on the kinetics of phenytoin. , 1985, British journal of clinical pharmacology.

[69]  J. Goldstein,et al.  Gene structure and upstream regulatory regions of human CYP2C9 and CYP2C18. , 1993, Biochemical and biophysical research communications.

[70]  J. Miners,et al.  Cotrimoxazole as an inhibitor of oxidative drug metabolism: effects of trimethoprim and sulphamethoxazole separately and combined on tolbutamide disposition. , 1985, British journal of clinical pharmacology.

[71]  J. Miners,et al.  Human hepatic cytochrome P450 2C9 catalyzes the rate-limiting pathway of torsemide metabolism. , 1995, The Journal of pharmacology and experimental therapeutics.

[72]  J. Miners,et al.  Validation of the tolbutamide metabolic ratio for population screening with use of sulfaphenazole to produce model phenotypic poor metabolizers , 1990, Clinical pharmacology and therapeutics.

[73]  F. Guengerich,et al.  Induction of various cytochromes CYP2B, CYP2C and CYP3A by phenobarbitone in non-human primates. , 1992, Pharmacogenetics.

[74]  R. Thomas,et al.  The metabolic fate of tolbutamide in man and in the rat. , 1966, Journal of medicinal chemistry.

[75]  J. Goldstein,et al.  Transcriptional regulation of human CYP2C genes: functional comparison of CYP2C9 and CYP2C18 promoter regions. , 1995, Biochemistry.

[76]  L. Aarons,et al.  Enoxacin‐warfarin interaction: Pharmacokinetic and stereochemical aspects , 1987, Clinical pharmacology and therapeutics.

[77]  D A Smith,et al.  Putative active site template model for cytochrome P4502C9 (tolbutamide hydroxylase). , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[78]  T. Inaba.  Phenytoin: pharmacogenetic polymorphism of 4'-hydroxylation. , 1990, Pharmacology & therapeutics.

[79]  S. Wrighton,et al.  The human hepatic cytochromes P450 involved in drug metabolism. , 1992, Critical reviews in toxicology.

[80]  A. D. Rodrigues,et al.  [O-methyl 14C]naproxen O-demethylase activity in human liver microsomes: evidence for the involvement of cytochrome P4501A2 and P4502C9/10. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[81]  P. Beaune,et al.  Purification and characterization of six cytochrome P-450 isozymes from human liver microsomes. , 1983, Biochemistry.

[82]  V. Aboyans,et al.  [Drug interactions]. , 2015, Journal of the Dental School, National University of Iran.

[83]  J. Miners,et al.  Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. , 1996, Methods in enzymology.

[84]  J. Hakkola,et al.  Expression of xenobiotic-metabolizing cytochrome P450 forms in human adult and fetal liver. , 1994, Biochemical pharmacology.

[85]  T. Leemann,et al.  In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.

[86]  R L Nation,et al.  Pharmacokinetic Drug Interactions with Phenytoin (Part II) , 1990, Clinical pharmacokinetics.

[87]  K. Adams,et al.  Effects of erythromycin or rifampin on losartan pharmacokinetics in healthy volunteers , 1998, Clinical pharmacology and therapeutics.

[88]  J. Miners,et al.  In vitro approaches can predict human drug metabolism. , 1993, Trends in pharmacological sciences.

[89]  J. Miners,et al.  Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. , 1991, Biochemical and biophysical research communications.

[90]  S. Waldman,et al.  A mutation in CYP2C9 is responsible for decreased metabolism of losartan , 1996 .

[91]  M. Gibaldi,et al.  The mechanism of the interaction between amiodarone and warfarin in humans , 1992, Clinical pharmacology and therapeutics.

[92]  E. Nelson,et al.  Kinetics of carboxytolbutamide excretion following tolbutamide and carboxytolbutamide administration. , 1961, The Journal of pharmacology and experimental therapeutics.

[93]  R. Weaver,et al.  Hydroxylation of the antimalarial drug 58C80 by CYP2C9 in human liver microsomes: comparison with mephenytoin and tolbutamide hydroxylations. , 1995, Biochemical pharmacology.

[94]  P. Poffenbarger,et al.  Pharmacogenetics of Tolbutamide Metabolism in Humans , 1978, Diabetes.

[95]  T. Andersson,et al.  A Study of the Interaction Between Omeprazole and Phenytoin in Epileptic Patients , 1990, Therapeutic drug monitoring.

[96]  R. Tukey,et al.  Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. , 1996, Biochemical pharmacology.

[97]  T. Leemann,et al.  In vitro oxidation of oxicam NSAIDS by a human liver cytochrome P450. , 1992, Life sciences.

[98]  J. Lasker,et al.  Human hepatic microsomal metabolism of delta 1-tetrahydrocannabinol. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[99]  H Furuya,et al.  Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy. , 1995, Pharmacogenetics.

[100]  Susan E. Wilson,et al.  Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E‐3174 , 1996, Clinical pharmacology and therapeutics.

[101]  R. Vestal,et al.  Drug metabolism in the elderly. , 1988, Pharmacology & therapeutics.

[102]  W. Trager,et al.  Warfarin-fluconazole. III. A rational approach to management of a metabolically based drug interaction. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[103]  R. Kato,et al.  Nucleotide sequence of a human liver cytochrome P-450 related to the rat male specific form. , 1987, Journal of biochemistry.

[104]  K. Siersbaek-Nielsen,et al.  The effect of different sulfonamides on phenytoin metabolism in man. , 2009, Acta medica Scandinavica. Supplementum.

[105]  M H Tarbit,et al.  Genetic analysis of the human cytochrome P450 CYP2C9 locus. , 1996, Pharmacogenetics.

[106]  L. Sansom,et al.  Lack of effect of erythromycin on the pharmacokinetics of single oral doses of phenytoin. , 1988, British journal of clinical pharmacology.

[107]  D. Back,et al.  Comparative effects of two antimycotic agents, ketoconazole and terbinafine on the metabolism of tolbutamide, ethinyloestradiol, cyclosporin and ethoxycoumarin by human liver microsomes in vitro. , 1989, British journal of clinical pharmacology.

[108]  L. Wienkers,et al.  Warfarin-fluconazole. I. Inhibition of the human cytochrome P450-dependent metabolism of warfarin by fluconazole: in vitro studies. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[109]  G. Shenfield,et al.  The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism. , 1996, Pharmacogenetics.

[110]  F. Gonzalez,et al.  Molecular genetics of the P-450 superfamily. , 1990, Pharmacology & therapeutics.

[111]  A. Richens,et al.  Disposition of Anticonvulsants in Childhood , 1989, Clinical pharmacokinetics.

[112]  X. Ponsoda,et al.  Metabolism of aceclofenac in humans. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[113]  M. Lai,et al.  Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. , 1995, Pharmacogenetics.

[114]  J. Miners,et al.  Tolbutamide hydroxylation in humans: lack of bimodality in 106 healthy subjects. , 1993, Pharmacogenetics.

[115]  O. Gotoh,et al.  Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. , 1992, The Journal of biological chemistry.

[116]  A. M. Baciewicz,et al.  Carbamazepine drug interactions. , 1986, Therapeutic drug monitoring.

[117]  J. Miners,et al.  Failure of 'therapeutic' doses of beta-adrenoceptor antagonists to alter the disposition of tolbutamide and lignocaine. , 1984, British journal of clinical pharmacology.

[118]  I. Niopas,et al.  Further insight into the stereoselective interaction between warfarin and cimetidine in man. , 1991, British journal of clinical pharmacology.

[119]  G. Neugebauer,et al.  Pharmacokinetics and metabolism of torasemide in man. , 1988, Arzneimittel-Forschung.

[120]  F. Gonzalez,et al.  Human cytochromes P450: problems and prospects. , 1992, Trends in pharmacological sciences.

[121]  R. Edwards,et al.  Expression of xenobiotic-metabolizing cytochrome P450 forms in human full-term placenta. , 1996, Biochemical pharmacology.

[122]  F. Guengerich,et al.  Cloning and sequence determination of a complementary DNA related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylase. , 1987, Biochemistry.

[123]  M. Ferrari,et al.  Inheritance of poor phenytoin parahydroxylation capacity in a Dutch family , 1988, Clinical pharmacology and therapeutics.

[124]  M. Relling,et al.  Tolbutamide and mephenytoin hydroxylation by human cytochrome P450s in the CYP2C subfamily. , 1990, The Journal of pharmacology and experimental therapeutics.

[125]  R. Kato,et al.  Hepatic microsomal tolbutamide hydroxylation in Japanese: in vitro evidence for rapid and slow metabolizers. , 1993, Pharmacogenetics.

[126]  J. Idle,et al.  The role of individual human cytochromes P450 in drug metabolism and clinical response. , 1992, Trends in pharmacological sciences.

[127]  T. Aoyama,et al.  Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. , 1992, Chemical research in toxicology.

[128]  P. Nolan,et al.  Pharmacokinetic interaction between intravenous phenytoin and amiodarone in healthy volunteers , 1989, Clinical pharmacology and therapeutics.

[129]  J. Miners,et al.  Allelic and functional variability of cytochrome P4502C9. , 1997, Pharmacogenetics.

[130]  P. Blain,et al.  Steady-state Pharmacokinetics of Phenytoin from Routinely Collected Patient Data , 1983, Clinical pharmacokinetics.

[131]  L. Skovsted,et al.  Sulfamethizole‐induced inhibition of diphenylhydantoin, tolbutamide, and warfarin metabolism , 1975, Clinical pharmacology and therapeutics.

[132]  M. Kristensen,et al.  The effect of different oral anticoagulants on diphenylhydantoin (DPH) and tolbutamide metabolism. , 2009, Acta medica Scandinavica.

[133]  F. Gonzalez,et al.  cDNA and amino acid sequences of two members of the human P450IIC gene subfamily. , 1987, Nucleic acids research.

[134]  Jerome J. Schentag,et al.  Effect of fluconazole on the disposition of phenytoin , 1991, Clinical pharmacology and therapeutics.

[135]  J. Miners,et al.  Drug glucuronidation in humans. , 1991, Pharmacology & therapeutics.